Award
NIH Reporter #5R01AG088141-02
Nicotinamide Adenine Dinucleotide Augmentation to Prevent or Reverse the Progression of Alzheimer's Disease in People with Down Syndrome
Recipient
Brigham and Women's Hospital, Boston, MA, United States
Award Amount
$801,611.00
Ceiling
$801,611.00
Awarded
September 09, 2026
Identifier
5R01AG088141-02
This NIH-funded project studies the safety and effects of NMN to address Alzheimer's Disease in adults with Down syndrome through a clinical trial.
Description
A phase 1, randomized, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Nicotinamide mononucleotide (NMN) in adults with Down syndrome, aiming to prevent or reverse Alzheimer's Disease progression.